Dr. Galardi is a founder of Apogenics, Inc., leading the commercial operations team in healthcare marketing. He was previously Vice President of Corporate Development at AmerisourceBergen Specialty Group. He was responsible for helping grow that business from $600M in sales to over $9B in a 10-year period. He was head of Trade Development at Bergen Brunswig.
He has worked for Aetna, as Regional Product Director, were he developed a variety of clinical, quality and sales programs. He was Director of National Program Development at Prudential Healthcare and helped develop the 3-tier formulary benefit model used today. He has developed disease state management programs and chaired various benefit coverage committees within a number of managed care organizations. He has developed successful disease management programs for oncology, autoimmune, neurologic, and infectious disease, including the first managed care protocol endorsing the use of triple-drug therapy for the treatment of HIV infection. He has chaired various benefits coverage and health policy committees within a number of managed care organizations.
Dr. Galardi is a recognized expert in the development of Risk Management and Risk Evaluation and Mitigation Strategies (REMS) and their design (including DEA Schedule II medications), with special focus on the development of commercially reasonable risk management and safe use practices. He has written and/or participated in the implementation and operations of most of the FDA approved REMS. His risk and safety work has covered all aspect of the supply chain including that of the role of: wholesaler, specialty distributor, third-party logistics, hospital, physician practices and ambulatory sites of care. He focuses his efforts on what is most likely to help the patients.
He trained at the Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania after receiving his Bachelors and Doctorate in Pharmacy from the Philadelphia College of Pharmacy and Science. Dr. Galardi is a board member of Women’s Campaign International and a former board member of Medical Claims Liaison and the Chronic Disease Fund.